ZOKINVY Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Zokinvy, and when can generic versions of Zokinvy launch?
Zokinvy is a drug marketed by Sentynl Theraps Inc and is included in one NDA. There are two patents protecting this drug.
This drug has nine patent family members in six countries.
The generic ingredient in ZOKINVY is lonafarnib. One supplier is listed for this compound. Additional details are available on the lonafarnib profile page.
DrugPatentWatch® Generic Entry Outlook for Zokinvy
Zokinvy was eligible for patent challenges on November 20, 2024.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be November 20, 2027. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ZOKINVY?
- What are the global sales for ZOKINVY?
- What is Average Wholesale Price for ZOKINVY?
Summary for ZOKINVY
International Patents: | 9 |
US Patents: | 2 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 73 |
Patent Applications: | 4,663 |
Drug Prices: | Drug price information for ZOKINVY |
What excipients (inactive ingredients) are in ZOKINVY? | ZOKINVY excipients list |
DailyMed Link: | ZOKINVY at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for ZOKINVY
Generic Entry Date for ZOKINVY*:
Constraining patent/regulatory exclusivity:
TREATMENT OF HUTCHINSON-GILFORD PROGERIA SYNDROME (HGPS) AND PROGEROID LAMINOPATHIES NDA:
Dosage:
CAPSULE;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for ZOKINVY
US Patents and Regulatory Information for ZOKINVY
ZOKINVY is protected by two US patents and two FDA Regulatory Exclusivities.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of ZOKINVY is ⤷ Sign Up.
This potential generic entry date is based on TREATMENT OF HUTCHINSON-GILFORD PROGERIA SYNDROME (HGPS) AND PROGEROID LAMINOPATHIES.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting ZOKINVY
Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: REDUCING THE RISK OF MORTALITY IN HUTCHINSON-GILFORD PROGERIA SYNDROME (HGPS)
Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: REDUCING THE RISK OF MORTALITY IN HUTCHINSON-GILFORD PROGERIA SYNDROME (HGPS)
FDA Regulatory Exclusivity protecting ZOKINVY
TREATMENT OF HUTCHINSON-GILFORD PROGERIA SYNDROME (HGPS) AND PROGEROID LAMINOPATHIES
Exclusivity Expiration: ⤷ Sign Up
NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Sign Up
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sentynl Theraps Inc | ZOKINVY | lonafarnib | CAPSULE;ORAL | 213969-001 | Nov 20, 2020 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Sentynl Theraps Inc | ZOKINVY | lonafarnib | CAPSULE;ORAL | 213969-002 | Nov 20, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Sentynl Theraps Inc | ZOKINVY | lonafarnib | CAPSULE;ORAL | 213969-001 | Nov 20, 2020 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for ZOKINVY
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
EigerBio Europe Limited | Zokinvy | lonafarnib | EMEA/H/C/005271 Zokinvy is indicated for the treatment of patients 12 months of age and older with a genetically confirmed diagnosis of Hutchinson-Gilford progeria syndrome or a processing-deficient progeroid laminopathy associated with either a heterozygous LMNA mutation with progerin-like protein accumulation or a homozygous or compound heterozygous ZMPSTE24 mutation. |
Authorised | no | no | yes | 2022-07-18 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for ZOKINVY
See the table below for patents covering ZOKINVY around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
European Patent Office | 1552020 | GENE LMNA ET SON IMPLICATION DANS LE SYNDROME D'HUTCHINSON-GILFORD ET L'ARTERIOSCLEROSE (LMNA GENE AND ITS INVOLVEMENT IN HUTCHINSON-GILFORD PROGERIA SYNDROME (HGPS) AND ARTERIOSCLEROSIS) | ⤷ Sign Up |
Canada | 2501464 | GENE LMNA ET SON IMPLICATION DANS LE SYNDROME D'HUTCHINSON-GILFOR D ET L'ARTERIOSCLEROSE (LMNA GENE AND ITS INVOLVEMENT IN HUTCHINSON-GILFORD PROGERIASYNDROME (HGPS) AND ARTERIOSCLEROSIS) | ⤷ Sign Up |
Australia | 2003301446 | LMNA GENE AND ITS INVOLVEMENT IN HUTCHINSON-GILFORD PROGERIA SYNDROME (HGPS) AND ARTERIOSCLEROSIS | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |